Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

Corporate Deck January 2022

HCW Presentation September 13, 2021

Corporate Deck August 2021

Canaccord Presentation August 12, 2021

Wedbush Presentation August 11, 2021

Corporate Deck July 2021

Corporate Deck June 2021

Corporate Deck May 2021 v2

1 2 3 5

Press Releases

ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

press release

December 17, 2021

-European Commission Decision Anticipated in Q1 2022- -CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by…

Read more

ObsEva Appoints Will Brown as Chief Financial Officer

press release

December 13, 2021

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – December 13, 2021…

Read more

ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

press release

December 10, 2021

-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10…

Read more
1 2 3 4 70

General Meetings

ObsEva Extraordinary General Meeting 2018

January 28, 2018

Read more

ObsEva Annual General Meeting 2017

June 13, 2017

Read more
1 2 3

Upcoming Events

Sorry, there are no events available yes.

 

Contacts

ObsEva Switzerland Office

Chemin des Aulx,12

1228, Plan-Les-Ouates, Geneva, Switzerland

+41 (0)22 552 3840


contact@obseva.ch

Media

Shauna Dillon

+41 (0)22 552 1550 Office

+41 79 360 3533 Mobile

shauna.dillon@obseva.ch

Investor relations


.


Joyce Allaire

+1 (617)-435-6602

ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

    * Type:


    InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue